To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma

Background: Endometrial cancer is one of the most commonly diagnosed cancers in women worldwide. Aim and Objectives: To study the expression of estrogen receptor (ER), progesterone receptor (PR) and p53 immunohistochemistry (IHC) markers in subtyping endometrial carcinoma. Materials and Methods: A t...

Full description

Saved in:
Bibliographic Details
Main Authors: Anuja Yadav, Anuradha Sistla, Meenakshi Swain, Swarnalata Gowrishankar, Michelle de Padua, Tejal Modi, Rallabandi Himabindu, Neha Agarwal, Aditya Kulkarni, Trilok Bhandari, Hemanth Vudayaraju, Chinnababu, Vijay A. Reddy
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-07-01
Series:Indian Journal of Pathology and Microbiology
Subjects:
Online Access:https://journals.lww.com/10.4103/ijpm.ijpm_568_22
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832591242039394304
author Anuja Yadav
Anuradha Sistla
Meenakshi Swain
Swarnalata Gowrishankar
Michelle de Padua
Tejal Modi
Rallabandi Himabindu
Neha Agarwal
Aditya Kulkarni
Trilok Bhandari
Hemanth Vudayaraju
Chinnababu
Vijay A. Reddy
author_facet Anuja Yadav
Anuradha Sistla
Meenakshi Swain
Swarnalata Gowrishankar
Michelle de Padua
Tejal Modi
Rallabandi Himabindu
Neha Agarwal
Aditya Kulkarni
Trilok Bhandari
Hemanth Vudayaraju
Chinnababu
Vijay A. Reddy
author_sort Anuja Yadav
collection DOAJ
description Background: Endometrial cancer is one of the most commonly diagnosed cancers in women worldwide. Aim and Objectives: To study the expression of estrogen receptor (ER), progesterone receptor (PR) and p53 immunohistochemistry (IHC) markers in subtyping endometrial carcinoma. Materials and Methods: A total of 100 cases of carcinoma endometrium submitted during January 2016 to October 2018 were included in our study. The ER, PR and p53 expressions were scored as per the adopted scoring system. Agreement between ER, PR and p53 IHC expression and the consensus HE diagnosis, FIGO grading and tumour staging were assessed using Chi square tests. Results: There was a statistical association between ER, PR and p53 status and tumour histologic type with a P value < 0.01. There was no statistical significance observed between ER and PR expressions and different FIGO grades. Statistical significance (P = 0.036) between p53 and different FIGO grades seen. No statistical significance was observed between ER, PR and p53 expressions and different tumour stages and tumour invasiveness. There was a statistical association between ER and PR status and lymph node metastasis. p53 did not show a statistical significance. Conclusion: Combination of ER, PR and p53 IHC markers can be used to distinguish type 1 and type 2 endometrial cancers. PR expression is more specific than ER in endometrioid carcinomas. p53 expression is more specific in serous carcinoma, however, p53 IHC alone cannot be used to distinguish different grades of endometrioid carcinomas as there is variability of staining in endometrioid carcinomas.
format Article
id doaj-art-82f0f01ccd2c43d985a6aee74b0d5b35
institution Kabale University
issn 0377-4929
0974-5130
language English
publishDate 2023-07-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Pathology and Microbiology
spelling doaj-art-82f0f01ccd2c43d985a6aee74b0d5b352025-01-22T15:09:10ZengWolters Kluwer Medknow PublicationsIndian Journal of Pathology and Microbiology0377-49290974-51302023-07-01671626710.4103/ijpm.ijpm_568_22To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinomaAnuja YadavAnuradha SistlaMeenakshi SwainSwarnalata GowrishankarMichelle de PaduaTejal ModiRallabandi HimabinduNeha AgarwalAditya KulkarniTrilok BhandariHemanth VudayarajuChinnababuVijay A. ReddyBackground: Endometrial cancer is one of the most commonly diagnosed cancers in women worldwide. Aim and Objectives: To study the expression of estrogen receptor (ER), progesterone receptor (PR) and p53 immunohistochemistry (IHC) markers in subtyping endometrial carcinoma. Materials and Methods: A total of 100 cases of carcinoma endometrium submitted during January 2016 to October 2018 were included in our study. The ER, PR and p53 expressions were scored as per the adopted scoring system. Agreement between ER, PR and p53 IHC expression and the consensus HE diagnosis, FIGO grading and tumour staging were assessed using Chi square tests. Results: There was a statistical association between ER, PR and p53 status and tumour histologic type with a P value < 0.01. There was no statistical significance observed between ER and PR expressions and different FIGO grades. Statistical significance (P = 0.036) between p53 and different FIGO grades seen. No statistical significance was observed between ER, PR and p53 expressions and different tumour stages and tumour invasiveness. There was a statistical association between ER and PR status and lymph node metastasis. p53 did not show a statistical significance. Conclusion: Combination of ER, PR and p53 IHC markers can be used to distinguish type 1 and type 2 endometrial cancers. PR expression is more specific than ER in endometrioid carcinomas. p53 expression is more specific in serous carcinoma, however, p53 IHC alone cannot be used to distinguish different grades of endometrioid carcinomas as there is variability of staining in endometrioid carcinomas.https://journals.lww.com/10.4103/ijpm.ijpm_568_22endometrial carcinomaestrogen receptorprogesterone receptorp53subtypes
spellingShingle Anuja Yadav
Anuradha Sistla
Meenakshi Swain
Swarnalata Gowrishankar
Michelle de Padua
Tejal Modi
Rallabandi Himabindu
Neha Agarwal
Aditya Kulkarni
Trilok Bhandari
Hemanth Vudayaraju
Chinnababu
Vijay A. Reddy
To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
Indian Journal of Pathology and Microbiology
endometrial carcinoma
estrogen receptor
progesterone receptor
p53
subtypes
title To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
title_full To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
title_fullStr To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
title_full_unstemmed To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
title_short To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
title_sort to study the expression of estrogen progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
topic endometrial carcinoma
estrogen receptor
progesterone receptor
p53
subtypes
url https://journals.lww.com/10.4103/ijpm.ijpm_568_22
work_keys_str_mv AT anujayadav tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT anuradhasistla tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT meenakshiswain tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT swarnalatagowrishankar tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT michelledepadua tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT tejalmodi tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT rallabandihimabindu tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT nehaagarwal tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT adityakulkarni tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT trilokbhandari tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT hemanthvudayaraju tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT chinnababu tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma
AT vijayareddy tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma